Please use this identifier to cite or link to this item: https://doi.org/10.1186/s40478-014-0175-x
DC FieldValue
dc.titleLongitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: Rapid reversal by anti-Aß agents
dc.contributor.authorQi, Y
dc.contributor.authorKlyubin, I
dc.contributor.authorHarney, S.C
dc.contributor.authorHu, N.W
dc.contributor.authorCullen, W.K
dc.contributor.authorGrant, M.K
dc.contributor.authorSteffen, J
dc.contributor.authorWilson, E.N
dc.contributor.authorDo Carmo, S
dc.contributor.authorRemy, S
dc.contributor.authorFuhrmann, M
dc.contributor.authorAshe, K.H
dc.contributor.authorCuello, A.C
dc.contributor.authorRowan, M.J
dc.date.accessioned2020-10-30T01:56:39Z
dc.date.available2020-10-30T01:56:39Z
dc.date.issued2014
dc.identifier.citationQi, Y, Klyubin, I, Harney, S.C, Hu, N.W, Cullen, W.K, Grant, M.K, Steffen, J, Wilson, E.N, Do Carmo, S, Remy, S, Fuhrmann, M, Ashe, K.H, Cuello, A.C, Rowan, M.J (2014). Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: Rapid reversal by anti-Aß agents. Acta Neuropathologica Communications 2 (1) : 175. ScholarBank@NUS Repository. https://doi.org/10.1186/s40478-014-0175-x
dc.identifier.issn20515960
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/182027
dc.description.abstractLong before synaptic loss occurs in Alzheimer's disease significant harbingers of disease may be detected at the functional level. Here we examined if synaptic long-term potentiation is selectively disrupted prior to extracellular deposition of Aß in a very complete model of Alzheimer's disease amyloidosis, the McGill-R-Thy1-APP transgenic rat. Longitudinal studies in freely behaving animals revealed an age-dependent, relatively rapid-onset and persistent inhibition of long-term potentiation without a change in baseline synaptic transmission in the CA1 area of the hippocampus. Thus the ability of a standard 200 Hz conditioning protocol to induce significant NMDA receptor-dependent short- and long-term potentiation was lost at about 3.5 months of age and this deficit persisted for at least another 2-3 months, when plaques start to appear. Consistent with in vitro evidence for a causal role of a selective reduction in NMDA receptor-mediated synaptic currents, the deficit in synaptic plasticity in vivo was associated with a reduction in the synaptic burst response to the conditioning stimulation and was overcome using stronger 400 Hz stimulation. Moreover, intracerebroventricular treatment for 3 days with an N-terminally directed monoclonal anti- human Aß antibody, McSA1, transiently reversed the impairment of synaptic plasticity. Similar brief treatment with the BACE1 inhibitor LY2886721 or the ?-secretase inhibitor MRK-560 was found to have a comparable short-lived ameliorative effect when tracked in individual rats. These findings provide strong evidence that endogenously generated human Aß selectively disrupts the induction of long-term potentiation in a manner that enables potential therapeutic options to be assessed longitudinally at the pre-plaque stage of Alzheimer's disease amyloidosis. © 2014 Qi et al.; licensee BioMed Central.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectamyloid beta protein
dc.subjectamyloid precursor protein
dc.subjectantibody
dc.subjectaspartic proteinase
dc.subjectBace protein, rat
dc.subjectfused heterocyclic rings
dc.subjectMRK 560
dc.subjectN-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide
dc.subjectpicolinic acid derivative
dc.subjectsecretase
dc.subjectsulfonamide
dc.subjectage
dc.subjectAlzheimer disease
dc.subjectanimal
dc.subjectanimal behavior
dc.subjectantagonists and inhibitors
dc.subjectdisease model
dc.subjectdrug effects
dc.subjectgenetics
dc.subjecthippocampus
dc.subjecthuman
dc.subjectimmunology
dc.subjectlong term potentiation
dc.subjectmale
dc.subjectmetabolism
dc.subjectpathophysiology
dc.subjectphysiology
dc.subjectrat
dc.subjectsynaptic transmission
dc.subjecttransgenic rat
dc.subjectWistar rat
dc.subjectAge Factors
dc.subjectAlzheimer Disease
dc.subjectAmyloid beta-Peptides
dc.subjectAmyloid beta-Protein Precursor
dc.subjectAmyloid Precursor Protein Secretases
dc.subjectAnimals
dc.subjectAntibodies
dc.subjectAspartic Acid Endopeptidases
dc.subjectBehavior, Animal
dc.subjectDisease Models, Animal
dc.subjectHeterocyclic Compounds, 2-Ring
dc.subjectHippocampus
dc.subjectHumans
dc.subjectLong-Term Potentiation
dc.subjectMale
dc.subjectPicolinic Acids
dc.subjectRats
dc.subjectRats, Transgenic
dc.subjectRats, Wistar
dc.subjectSulfonamides
dc.subjectSynaptic Transmission
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1186/s40478-014-0175-x
dc.description.sourcetitleActa Neuropathologica Communications
dc.description.volume2
dc.description.issue1
dc.description.page175
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s40478-014-0175-x.pdf1.29 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons